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Future programs in the basic and clinical sciences on surfactant
stimulation and substitution
Moderator: Michael Obladen
OBLADEN: The first problem we should approach
is the surfactant researcher's fear: Is my material
the right stuff? Dr. HALLMAN, should an exogen-
ous surfactant contain protein, and which protein?
HALLMAN: Right now we have two types of apo-
proteins, one is the 34 KD, which is not lipid
soluble, but contains many hydrophobic and hy-
drophilic portions and also some collagen-like
structures. Then there is the low molecular prote-
olipid that seems to enhance the adsorbtion of
surfactant. It makes the adsorbtion of synthetic
phospholipids remarkably faster when we add the
proteolipid.
MORLEY: I have presented results today, that an
artificial surfactant which contains no apoproteins
has beneficial effects. I think apoproteins can be
found in association with surfactant. Their exact
function still remains to be demonstrated. It may
be, that our surfactant mixes with apoproteins
present in the trachea.
ENHORNING: Dr. MORLEY, to be honest with you
I think there is a problem with your artificial
surfactant that its adsorbtion rate is very low. And
I think this is the reason why you don't see the
immediate effect. The long term effect, lowering
the mortality, probably is due to recirculation of
the phospholipids you have introduced. My feel-
ing is an advantage of giving surfactant before the
first breath. If you give it later on, there is already
damage to the airway and subsequent protein
leakage.
SAUGSTAD: I feel, Dr. MORLEY'S data would be
different with something else than saline as pla-
cebo. We have now data on the newborn rabbit
showing that there is a clear dose response relation
between saline volume and decreased compliance.
And as I understand, Dr. MORLEY gives up to
three ml of saline in the first hour to the control
group.
MORLEY: Having seen the data that other people
have produced, I probably would not use saline
for control any more. However, if one thinks to
pour two ml of saline down the trachea is harmful,
neonatologists around the world need to rethink
tracheal toilet as a lavage, because well over 75%
of the neonatal units in England use approxi-
mately one ml of saline for tracheal toilet. The
fact is that there is saline in our surfactant. If
saline per se is harmful and our surfactant was a
suspension, then equal effects should have come
from the saline mixed in the surfactant.
OBLADEN: We also should speak about side effects.
Circulating antibodies have been demonstrated
and they have not only been demonstrated after
treatment with material of animal origin. They
even have been demonstrated after RDS without
any supplementation. I would like to ask Dr.
HALLMAN and Dr. ENHORNING to comment on
the potential significance of immunization due to
administration of exogenous proteins.
ENHORNING: If you give only one dose and give it
to very preterm infants with a poor immunological
response, I don't think you have to worry much.
Furthermore, these infants are fed cow's milk and
certainly they very often inhale some of the milk.
So there is a chance of getting the antigen down
the airways even if you don't give surfactant.
HALLMAN: I agree completely. It is very unlikely
that there are serious immunological side effects.
Dr. STRAYER, who is an expert in immunology,
has measured immune complexes and also specific
immune complexes. They were not increased by
human surfactant.
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WEITZEL: Dr. HALLMAN, you have shown a reduc-
tion of CH 50 activity or even C 3 activity, and I
guess you used a plate test?
HALLMAN: We have also been using C 13 and we
compared surfactant versus placebo and didn't
see any difference.
ROOTH: You have a tremendous vascular dilata-
tion when Pco2 is up in the beginning of RDS and
so the stage is set for disastrable side effects. You
are speaking of the immediate effect of saving the
lungs, but I think we also have to look into the
future and to consider the reactions of the brain.
OBLADEN: I think everyone who has been doing
rescue studies has observed relapses. I would like
to ask those people who have done prevention
studies: Do you see relapses?
HALLMAN: Well, first of all it is a matter of dosage.
We formerly used 60 mg and now in the new trial
went up to 80 mg. With this dosage and with
really sick immature babies we do see a relapse,
and I would almost say that you can use anything,
you will see relapse in any surfactant. Right now,
our policy is not to wait for the relapse: We are
aggressively giving more, if it looks like that the
baby does not go close to 21 % of oxygen. And if
the baby's chest still doesn't move, we give more.
OBLADEN: Nearly every researcher uses different
success criteria in his study. Dr. HALLMAN, if I
would squeeze you now to restrict yourself to
three success criteria and not look for any more
than just these three, which three would you pick?
HALLMAN: Long term death and overall BPD inci-
dence. Then there would be ventilatory index
which would include mean airway pressure, FiCh
and Ρθ2.
OBLADEN: Dr. MORLEY, you measured compliance
and you explained to us compliance is difficult to
measure. In some infants it is not possible to
measure it at all.
MORLEY: Measuring compliance of these tiny ba-
bies is extremely difficult and extremely unreliable.
I do not put great faith in the absolute compliance
measurement for each baby.
OBLADEN: Could we speak a little about the group
of infants who are non-responders? Do you see
them?
MORLEY: Yes, we see non-responders. Quite a lot
of our non-responders are babies who are too
mature to respond. They are doing well anyway.
ENHORNING: In a rescue study we saw one non-
responder out of six. But this was severely affected
by RDS when the surfactant was given, the baby
was severly damaged in his airways. Furthermore,
there were practical problems in instillation of the
surfactant in that case. It probably never came to
the trachea.
HALLMAN: We have a total of four non-re-
sponders, two are in a rescue study and two in a
prophylactic study. I would prefer to talk about
poor response. The problem is, you are treating
them already with very high pressures, you give
surfactant, you get an increase in oxygen, but you
cannot go down with the ventilator pressures and
at autopsy they may have massive hyaline mem-
branes.
OBLADEN: The next point is future: What to do
when to plan a study? To which gestational age
should it be restricted? Which material should be
taken? How should it be dosed? How often should
it be given? Should both rescue and prevention
studies be performed? Pilot versus control versus
blind versus deaf? Every experienced nurse using
a stethoscope will immediately hear if a baby has
received surfactant or not. Should the controls be
bagged, should they remain untreated, should they
receive placebo?
ENHORNING: The lower the gestational age, the
greater the chance to find an effect with a limited
number of cases. In prevention studies you have
a better chance to see an effect, but there is a need
for rescue studies too, no question. I think pilot
studies on surfactant supplementation are not to-
lerable any more, because it is too clear that it
works. Of course studies should be controlled and
should be blinded as far as you can. Saline for
the controls is not justified because you might put
your control in a worse situation.
OBLADEN: I will try to sum up what we have heard:
Surfactant supplementation cannot be termed as
standard clinical treatment but must be performed
on an investigative basis. For prevention studies,
we will need several hundred infants below 30
weeks' gestation for significant results. We need a
close look on side effects. It is still open if surfac-
tant supplementation contributes to ductus ar-
teriosus, to lung bleeding, to intraventricular he-
morrhage and to circulatory disturbancies. It
would be very valuable if common endpoints
could be found to make the different published
studies more comparable to each other. I think it is
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In diesem Werk stellen Grundlagenforscher und Kliniker die Repro-
duktionsmedizin als interdisziplinäre ärztliche Aufgabe dar. Es werden
sowohl die dominierenden Aspekte der Pathophysiologie aus der täg-
lichen Praxis als auch das klinische Management der Fortpflanzungs-
störungen bei Mann und Frau abgehandelt. Die Autoren sind aus-
gewiesene Experten in der experimentellen und klinischen Grund-
lagenforschung, die ihre langjährigen eigenen Erfahrungen aus der :
Klinik für die Praxis lesbar gemacht haben.
So wendet sich das Werk sowohl an den praktizierenden Arzt als
auch an den forschenden Kliniker. Sein Ziel ist es, allen beteiligten
Fachkollegen ein gemeinsames wissenschaftliches Fundament für
weitere Forschungen und Erfolge in der Fertilitätsforschung zur
Verfügung zu stellen.
Aufgrund des interdisziplinären Charakters dieses Werkes ist eine
ganze Reihe medizinischer Fachgebiete direkt angesprochen: Frauen-
heilkunde und Geburtshilfe, Andrologie, Urologie, Dermatologie,
Pädiatrie, Endokrinologie, Genetik, Immunologie und Allgennein-
medizin.
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